On Nov 07, major Wall Street analysts update their ratings for $Sarepta Therapeutics (SRPT.US)$, with price targets ranging from $167 to $210.
Morgan Stanley analyst Michael Ulz maintains with a buy rating, and maintains the target price at $200.
BofA Securities analyst Tazeen Ahmad maintains with a buy rating, and maintains the target price at $210.
Barclays analyst Gena Wang maintains with a buy rating, and adjusts the target price from $203 to $209.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $203.
Baird analyst Brian Skorney maintains with a buy rating, and adjusts the target price from $200 to $193.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Sarepta's recent third-quarter results surpassed expectations with significant beats in both total and Elevidys revenue. The company's maintained guidance for Elevidys is perceived to be on the cautious side.
Sales of Elevidys exhibited growth surpassing expectations in the third quarter, accompanied by positive remarks from management regarding its market introduction. Analysts believe the indicators are consistently suggesting that Elevidys has the potential to evolve into a multi-billion-dollar product, which could be further augmented by a series of gene therapy releases anticipated over the forthcoming five years.
Here are the latest investment ratings and price targets for $Sarepta Therapeutics (SRPT.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月7日，多家华尔街大行更新了$Sarepta Therapeutics (SRPT.US)$的评级，目标价介于167美元至210美元。
摩根士丹利分析师Michael Ulz维持买入评级，维持目标价200美元。
美银证券分析师Tazeen Ahmad维持买入评级，维持目标价210美元。
巴克莱银行分析师Gena Wang维持买入评级，并将目标价从203美元上调至209美元。
TD Cowen分析师Ritu Baral维持买入评级，维持目标价203美元。
贝雅分析师Brian Skorney维持买入评级，并将目标价从200美元下调至193美元。
此外，综合报道，$Sarepta Therapeutics (SRPT.US)$近期主要分析师观点如下：
以下为今日9位分析师对$Sarepta Therapeutics (SRPT.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
